News Sentiment

VTVT sentiment intelligence

vTv Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 48 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 32.88 Week of 17 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

78/100 classification confidence.

Company focus 39

directly relevant articles

Source quality 4

high-authority source matches

Trend context Trend inactive

-1.8% over one week, -6.2% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Neutral

vTv Therapeutics (NASDAQ:VTVT) Stock Price Expected to Rise, BTIG Research Analyst Says

Market Reaction

Balanced read

61/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 78/100 classification
One-week reaction -1.8% Price digesting
Trend fit Trend inactive -6.2% over four weeks
Fair value 54.2% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 11
Neutral 33
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 39
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 15
Market source 9
MarketBeat 4
TradingView 3
simplywall.st 3
The Manila Times 2
dars.gov.et 1
Simply Wall St. 1

Event Lens

What the news is about

Classified themes
Market update 23
Earnings 17
Analyst action 4
Deals and strategy 2
Regulatory and legal 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 48
Stock Titan Direct company coverage

6,000 vTv Therapeutics (VTVT) options granted to director tied to Baker funds

vTv Therapeutics director Dr. Raymond Cheong received a grant of 6,000 non-qualified stock options, exercisable into Class A common stock at $35.08 per share. These options, vesting on June 26, 2027, or the 2027 annual shareholder meeting, are tied to Baker Bros.-affiliated funds

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 20:41
Source
Stock Titan
Stock Titan Direct company coverage

vTv Therapeutics (VTVT) director granted 6,000 stock options at $35.08

vTv Therapeutics director Daniel K. Spiegelman was granted 6,000 stock options to purchase Class A Common Stock at $35.08 per share. These options are part of his director compensation, expire in 2036, and will vest on the earlier of June 26, 2027, or the 2027 annual general meet

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 19:41
Source
Stock Titan
Stock Titan Direct company coverage

Director Fahed Al-Marzooqi (VTVT) granted 6,000 vTv Therapeutics stock options

Fahed Al-Marzooqi, a director at vTv Therapeutics Inc. (VTVT), was granted 6,000 stock options for Class A common stock with an exercise price of $35.08 per share. These options will vest on the earlier of June 26, 2027, or the 2027 annual general meeting, provided he continues h

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 19:41
Source
Stock Titan
Stock Titan Direct company coverage

Director at vTv Therapeutics (VTVT) receives 6,000 stock options grant

vTv Therapeutics director Anne M. Phillips was granted options to purchase 6,000 shares of Class A common stock at an exercise price of $35.08 per share. These options are part of her board compensation and will expire on June 26, 2036. The options vest on the earlier of June 26,

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 19:41
Source
Stock Titan
Stock Titan Direct company coverage

Director at vTv Therapeutics (VTVT) awarded 6,000 stock options grant

vTv Therapeutics director Srinivas Akkaraju was granted 6,000 stock options with an exercise price of $35.08 per share, expiring in 2036. These options will vest on the earlier of June 26, 2027, or the 2027 annual general meeting, provided Akkaraju continues serving on the board.

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 19:41
Source
Stock Titan
TradingView Direct company coverage

vTv Therapeutics, Inc. Class A Actuals & Estimates (NASDAQ:VTVT)

This article provides financial actuals and estimates for vTv Therapeutics Inc. (NASDAQ: VTVT), covering its stock performance, analyst forecasts, earnings, revenue, and other key financial metrics. It details the company's current stock price, historical highs and lows, market c

Tone
Positive 65/100
Event
Earnings
Published
26 Jun 2026 05:10
Source
TradingView
TradingView Direct company coverage

vTv Therapeutics, Inc. Class A Financial Disclosures & SEC Filings

This article provides a comprehensive list of vTv Therapeutics Inc.'s (VTVT) financial disclosures and SEC filings, including Forms 10-K, 10-Q, and 8-K. It details earnings releases and quarterly/annual reports from 2020 through Q1 2026, allowing users to evaluate the company's f

Tone
Neutral 50/100
Event
Earnings
Published
06 Jun 2026 21:09
Source
TradingView
Stock Titan Direct company coverage

Stock options, 10-year term: inside vTv Therapeutics grant

vTv Therapeutics (Nasdaq: VTVT) announced the grant of 2,500 stock options to a new non-executive employee as an inducement to employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $34.30, vest over four years, and have a 10-year ter

Tone
Neutral 50/100
Event
Market update
Published
06 Jun 2026 14:39
Source
Stock Titan
Market source Direct company coverage

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

vTv Therapeutics Inc., a late-stage biopharmaceutical company, announced it granted 2,500 stock options to a non-executive employee as an inducement to employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $34.30 per share and will v

Tone
Neutral 50/100
Event
Market update
Published
02 Jun 2026 15:05
Source
Market source
Sahm Direct company coverage

VTV Therapeutics (VTVT) Q1 Profit Swing To US$1.94 EPS Tests Bullish Narratives

VTV Therapeutics (VTVT) reported a significant shift in its Q1 2026 financials, moving from quarterly losses to a profit of US$1.94 EPS and US$36.8 million in revenue. This change raises questions about the durability of the new profit profile, especially given forecasts of a 20.

Tone
Neutral 50/100
Event
Earnings
Published
15 May 2026 01:40
Source
Sahm
Minichart Direct company coverage

vTv Therapeutics Inc. Files Form 8-K for Class A Common Stock on Nasdaq – Company Information and SEC Filing Details

vTv Therapeutics Inc. has filed a Form 8-K to announce a significant expansion of its at-the-market (ATM) equity offering program, increasing the aggregate offering price to up to $47,500,000. This move allows the company to raise substantial capital for operations, research, or

Tone
Negative 38/100
Event
Market update
Published
14 May 2026 08:40
Source
Minichart
Stock Titan Direct company coverage

Licensing windfall lifts vTv Therapeutics (NASDAQ: VTVT) to Q1 2026 profit and stronger cash

vTv Therapeutics (NASDAQ: VTVT) reported a significant financial turnaround in Q1 2026, achieving a net income of $24.1 million, a substantial improvement from a $6.2 million loss in the prior year. This profit was primarily driven by $36.8 million in licensing revenue, including

Tone
Neutral 50/100
Event
Earnings
Published
14 May 2026 00:39
Source
Stock Titan
Bitget Direct company coverage

Recent filings by vTv Therapeutics Inc. to the U.S. Securities and Exchange Commission (SEC) show that the company has increased its allocation of Class A common shares issued under the at-the-market offering (ATM) plan to the full amount.

vTv Therapeutics Inc. has filed with the U.S. SEC, indicating an increase in the allocation of Class A common shares under its at-the-market offering plan to the full authorized amount. This move signifies the company's intention to fully utilize its equity financing quota.

Tone
Neutral 50/100
Event
Market update
Published
13 May 2026 22:40
Source
Bitget
Stock Titan Direct company coverage

vTv Therapeutics (NASDAQ: VTVT) registers $47.5M ATM to fund cadisegliatin

vTv Therapeutics has registered an "at-the-market" (ATM) offering of up to $47.5 million in Class A common stock through TD Cowen to fund the development of its lead product candidate, cadisegliatin. The proceeds will support general corporate purposes, including manufacturing, c

Tone
Neutral 50/100
Event
Market update
Published
13 May 2026 21:40
Source
Stock Titan
Stock Titan Direct company coverage

vTv Therapeutics (VTVT) expands ATM share offering, files Dechert legal opinion

vTv Therapeutics Inc. (VTVT) has filed an 8-K to announce an expansion of its at-the-market (ATM) stock sales program. The company filed a prospectus supplement to increase the offered Class A common shares to the full amount allowed by the ATM agreement and included a legal opin

Tone
Negative 39/100
Event
Market update
Published
13 May 2026 21:40
Source
Stock Titan
Stock Titan Direct company coverage

[8-K] vTv Therapeutics Inc. Reports Material Event

vTv Therapeutics Inc. reported a significant turnaround in its first quarter of 2026, driven by a major licensing payment, resulting in $36.8 million in revenue and $24.1 million in net income. The company's cash position of $98.1 million is expected to fund operations through th

Tone
Positive 77/100
Event
Earnings
Published
13 May 2026 20:40
Source
Stock Titan
The Manila Times Direct company coverage

vTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

vTv Therapeutics (Nasdaq: VTVT) announced its first quarter 2026 financial results, highlighting the ongoing progress of its Phase 3 CATT1 trial for cadisegliatin, an investigational treatment for type 1 diabetes. The company expects to complete enrollment in the third quarter of

Tone
Positive 75/100
Event
Regulatory and legal
Published
13 May 2026 20:40
Source
The Manila Times
Stock Titan Direct company coverage

Oral type 1 diabetes drug advances: vTv expects cash through Phase 3 data

vTv Therapeutics reported a strong Q1 2026 with $36.8 million in revenue and $24.1 million in net income, boosting cash and equivalents to $98.1 million. The company is on track to complete enrollment for its Phase 3 CATT1 trial of cadisegliatin, an oral adjunctive therapy for ty

Tone
Positive 72/100
Event
Earnings
Published
13 May 2026 19:40
Source
Stock Titan